吡仑帕奈与肝酶诱导剂联合应用的研究进展  

Research Progress on the Combined Application of Perampanel and Liver Enzyme Inducer

作　　者：陈文静 聂磊[1] CHEN Wenjing;NIE Lei(The First Affiliated Hospital of Jiamusi University,Jiamusi 154000,China)

机构地区：[1]佳木斯大学附属第一医院,黑龙江佳木斯154000

出　　处：《工业微生物》2024年第5期4-6,共3页Industrial Microbiology

摘　　要：自2012年上市以来,作为以α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体为靶点的首个新型抗癫痫药物,吡仑帕奈现被广泛应用于癫痫治疗中,并取得了积极的疗效。癫痫是最常见的影响大脑机能的病症之一,病因复杂,现有的治疗手段仍以药物治疗为主,旨在减缓或防止病症发作。文章整理了国内外相关文献,阐述了吡仑帕奈联合肝酶诱导剂的疗效,并进一步探讨了其与抗癫痫药物的相互作用。Since its launch in 2012,as the first new anti-epileptic drug targeting AMPA receptors,perampanel has been widely used in the treatment of epilepsy,and has achieved positive efficacy.Epilepsy is one of the most common diseases affecting brain function,the etiology of which is complex.The existing treatment methods of epilepsy are still mainly drug symptomatic treatment,aiming to reduce or prevent seizures.This paper collates the relevant literature at home and abroad,describes the curative effect of perampanel combined with liver enzyme inducer,and further discusses the interaction of perampanel combined with liver enzyme inducer with anti-epileptic drugs.

关 键 词：癫痫 吡仑帕奈 肝酶诱导剂 联合应用 

分 类 号：R971.6[医药卫生—药品]